Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem

Dimas Seto Prasetyo; Herna Herna; Mursinah Mursinah; Fera Ibrahim; Budiman Bela

doi:10.22435/jki.v0i0.5008

Dimas Seto Prasetyo Departemen Mikrobiologi Fakultas Kedokteran Universitas Indonesia/KSM Mikrobiologi Klinik RSUPN dr Cipto Mangunkusumo, Jakarta, Indonesia
Herna Herna Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta, Indonesia
Mursinah Mursinah Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta, Indonesia
Fera Ibrahim Departemen Mikrobiologi Fakultas Kedokteran Universitas Indonesia/KSM Mikrobiologi Klinik RSUPN dr Cipto Mangunkusumo, Jakarta, Indonesia
Budiman Bela Departemen Mikrobiologi Fakultas Kedokteran Universitas Indonesia/KSM Mikrobiologi Klinik RSUPN dr Cipto Mangunkusumo, Jakarta, Indonesia

DOI: https://doi.org/10.22435/jki.v0i0.5008

Keywords: Combination, Checkerboard, In vitro activity, Carbapenem-resistant Pseudomonas aeruginosa

Abstract

Lower respiratory tract, sepsis, or urinary tract infection caused by the multidrug resistance Pseudomonas aeruginosa is common in the hospital, especially in the ICU wards. The treatment against this bacteria requires combination of antibiotics with different mechanism of actions. In this study, several combinations of antibiotics were evaluated in vitro against carbapenem-resistant P. aeruginosa isolated from the ICU of Cipto Mangunkusumo Hospital. The combination of antibiotics tested were ceftazidime-amikacin, ceftazidime-ciprofloxacin, and ciprofloxacin-amikacin. Checkerboard assay to the combination of antibiotics was conducted to assess the in vitro synergistic activity. A total of 22 P. aeruginosa isolates were collected, 16 of them were resistant to ceftazidime, ciprofloxacin, amikacin, as well as carbapenem. The result revealed that the combination of ceftazidime and amikacin showed promising synergistic activity. Conversely, no synergitic activities were shown by the combination of ceftazidime-ciprofloxacin and ciprofloxacin-amikacin. The combination of ceftazidime-amikacin may has potential effect againsts carbapenem-resistant P. aeruginosa in vitro.

References

MacVane SH. Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. Journal of Intensive Care Medicine. 2017;32(1):25-37.

Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Critical Care. 2016;20:136. DOI 10.1186/s13054-016-1320-7.

Karuniawati A, Saharman YR, Lestari DC. Detection of carbapenemase encoding genes in Enterobacteriace, Pseudomonas aeruginosa, and Acinetobacter baumanii isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. Acta Med Indones-Indones J Intern Med. 2013;45(2).

Banjare B, Barapatre R. Incidence of carbapenem-resistant Pseudomonas aeruginosa in clinical samples. International Journal of Biomedical Research. 2015;6(08):567-69.

Jenny M, Kingsbury J. Properties and prevention: a review of Pseudomonas aeruginosa. Journal of Biology and Medical Research. 2018;2(3):18.

Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have? Critical Care. 2014;18:229.

Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother. 2014;46(3):149-164.

Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T. Treatment options for carbapenem-resistant gram-negative infections. Dtsch Arztebl Int. 2018;115:345–52. DOI: 10.3238/arztebl.2018.0345.

Tangden T. Combination antibiotic therapy for multidrug-resistant gram-negative bacteria. Upsala Journal of Medical Sciences. 2014;119:149–53.

Clinical and Laboratory Standards Institute M100-S25. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. January 2015.

Synergism Testing: Broth Microdilution. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington DC: ASM Press; 2011.

Kateete DP, Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007–2009). SpringerPlus. 2016 Aug 9;5(1):1308. doi: 10.1186/s40064-016-2986-7.

Ciptaningtyas VR, Lestari ES, Wahyono H. Pseudomonas aeruginosa resistance in Southeast Asia. Sains Medika. 2019;10(2):84-92.

Hannan A, Gondal AJ, Saleem S, Arshad MU, Lateef W. In-vitro efficacy of ceftazidime in combinations with meropenem, piperacillin / tazobactam, amikacin and ciprofloxacin against extensively drug-resistant Pseudomonas aeruginosa. Pakistan J. Zool. 2014;46(4):1111-16.

Tunyapanyit W, Pruekprasert P, Laoprasopwattana K, Chelae S. In vitro effects of various antimicrobials alone and in combinations against imipenem-resistant Pseudomonas aeruginosa. Sains Malaysiana. 2019;48(5):1065–73.

Righi E, Scudeller L, Chiamenti M, Abdelraouf K, Lodise T, Carrara E, et al. In vivo studies on antibiotic combination for the treatment of carbapenem-resistant gram-negative bacteria: a systematic review and meta-analysis protocol. BMJ Open Science. 2020;4:e100055. doi:10.1136/bmjos-2019-100055.

Khan SN, Khan AU. Breaking the spell: combating multidrug resistant ‘superbugs’. Front. Microbiol. 2016;7(174):1-11. doi: 10.3389/fmicb.2016.00174.

Doi Y. Treatment options for carbapenem-resistant gram negative bacterial infections. CID. 2019 Nov 13;69(Suppl 7):S565-75. doi: 10.1093/cid/ciz830.

Adembri C, Novelli A, Nobili S. Some suggestions from PK/PD principles to contain resistance in the clinical setting-focus on ICU patients and gram-negative strains. Antibiotics. 2020 Oct 6;9(10):676. doi: 10.3390/antibiotics9100676.

Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6:a025247.

Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016 Jun 1;6(6):a027029. doi: 10.1101/cshperspect.a027029.

Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2017 Apr;23(4):234-41. doi:10.1016/j.cmi.2016.12.002.

Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination

therapy for multidrug-resistant gram-negative infections: systematic review and meta-analysis. Nature Scientific Reports. 2019 Oct 29;9(1):15290. doi: 10.1038/s41598-019-51711-x.